OnLume
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $300k | Grant | |
N/A | $700k | Early VC | |
$2.0m | Grant | ||
$7.0m | Series A | ||
* | N/A | $2.8m | Early VC |
Total Funding | CAD17.5m |
Related Content
Recent News about OnLume
EditOnLume, Inc., based in Madison, WI, is a medtech company specializing in fluorescence image-guided surgery (FGS). The company's core product, the OnLume Imaging System (OIS), has received 510k clearance from the U.S. Food and Drug Administration (FDA). This advanced imaging technology is designed to provide real-time visualization of blood flow and tissue perfusion during various surgical procedures, including vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. The system works in conjunction with FDA-approved indocyanine green (ICG) dye, enabling surgeons to achieve greater precision and improve patient outcomes.
OnLume serves a diverse range of clients, primarily hospitals and surgical centers, that perform complex surgeries requiring enhanced imaging capabilities. The company operates in the medical technology market, focusing on surgical imaging solutions. Its business model revolves around the sale and distribution of its imaging systems, as well as providing ongoing support and maintenance services to its clients. Revenue is generated through the direct sale of the OnLume Imaging System, as well as through service contracts and potential future upgrades.
The experienced team behind OnLume includes medtech entrepreneurs, medical imaging experts, and engineers, all committed to advancing surgical imaging technology. The company aims to increase the adoption of fluorescence-guided surgery techniques, thereby improving patient care and surgical outcomes.
Keywords: Fluorescence-guided surgery, imaging system, vascular surgery, gastrointestinal surgery, organ transplant, medical technology, real-time visualization, indocyanine green dye, surgical precision, patient outcomes.